Testing a drug for low platelets from cancer treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Women’s health & pregnancy clinical trials.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old
- You have ovarian, cervical, endometrial, or other gynecologic cancer confirmed by biopsy or cell analysis
- Your platelet count is low (under 75) because of your cancer treatment, and you have at least 2 more treatment cycles planned
- You are able to care for yourself (ECOG 0-1) and have a life expectancy of at least 12 weeks
- You must not be pregnant, not breastfeeding, and agree to use effective birth control during the study and for a week after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This Phase 2 study tests hetrombopag to treat chemotherapy-related low platelet counts in adults with acute myeloid leukemia (AML) in remission. It aims to help keep platelets up so you can safely continue chemotherapy.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
This study tests if a combination of two medications, hetrombopag (a pill) and rhTPO (an injection), can safely raise very low platelet counts in people with solid tumors caused by their cancer treatments. If you have low platelets due to chemo, radiation, or other therapies, this may offer a new option.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
Hear when a new Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.